Your browser is no longer supported. Please, upgrade your browser.
Settings
PSDV pSivida Corp. daily Stock Chart
PSDV [NASD]
pSivida Corp.
Index- P/E- EPS (ttm)-0.55 Insider Own0.10% Shs Outstand40.00M Perf Week-0.54%
Market Cap73.20M Forward P/E- EPS next Y-0.20 Insider Trans141.75% Shs Float36.87M Perf Month-14.08%
Income-18.80M PEG- EPS next Q-0.14 Inst Own25.90% Short Float0.74% Perf Quarter6.40%
Sales7.10M P/S10.31 EPS this Y-428.30% Inst Trans-8.00% Short Ratio0.38 Perf Half Y-0.54%
Book/sh0.36 P/B5.08 EPS next Y60.80% ROA-80.00% Target Price9.38 Perf Year-40.58%
Cash/sh0.39 P/C4.75 EPS next 5Y- ROE-119.80% 52W Range1.50 - 4.25 Perf YTD7.02%
Dividend- P/FCF- EPS past 5Y-9.00% ROI-103.40% 52W High-56.94% Beta1.28
Dividend %- Quick Ratio3.30 Sales past 5Y-20.10% Gross Margin- 52W Low22.00% ATR0.13
Employees20 Current Ratio3.30 Sales Q/Q100.00% Oper. Margin- RSI (14)42.54 Volatility5.52% 6.48%
OptionableYes Debt/Eq0.00 EPS Q/Q0.50% Profit Margin- Rel Volume0.62 Prev Close1.91
ShortableYes LT Debt/Eq0.00 EarningsAug 03 AMC Payout- Avg Volume718.28K Price1.83
Recom1.50 SMA20-9.54% SMA50-6.24% SMA200-10.18% Volume443,925 Change-4.19%
May-30-17Initiated Rodman & Renshaw Buy $8
Oct-15-15Initiated FBR Capital Outperform $6
Sep-29-14Reiterated Northland Capital Outperform $7 → $10
May-05-14Initiated MLV & Co Buy $6
Oct-18-13Reiterated Ladenburg Thalmann Buy $5 → $2.75
Oct-08-13Initiated Northland Capital Outperform $7
Apr-10-13Upgrade Ladenburg Thalmann Neutral → Buy $4
Nov-18-09Initiated Ladenburg Thalmann Buy $9
Jun-22-17 07:00AM  pSivida Submits Marketing Authorization Application (MAA) for Approval of Durasert Three-year Treatment for Posterior Segment Uveitis in the European Union GlobeNewswire
06:20AM  Watertowns pSivida files for European approval of treatment to prevent blindness American City Business Journals
Jun-14-17 08:00AM  Today's Research Reports on Stocks to Watch: SodaStream International and pSivida Corp. Accesswire
Jun-13-17 07:00AM  pSividas Durasert Three-year Treatment for Posterior Segment Uveitis Successfully Achieves Primary Efficacy Endpoint in Second Phase 3 Study GlobeNewswire -15.87%
Jun-09-17 06:36AM  Edited Transcript of PSDV earnings conference call or presentation 4-May-17 8:30pm GMT Thomson Reuters StreetEvents
Jun-07-17 07:30AM  Why This $1.00 Medical Device Stock is Set Up to Rip Accesswire
May-22-17 02:02PM  ETFs with exposure to pSivida Corp. : May 22, 2017 Capital Cube
May-11-17 05:23PM  ETFs with exposure to pSivida Corp. : May 11, 2017 Capital Cube
May-10-17 10:49AM  pSivida Corp. :PSDV-US: Earnings Analysis: Q3, 2017 By the Numbers : May 10, 2017 Capital Cube
May-08-17 09:15AM  Durasert Three-year Treatment for Posterior Segment Uveitis Significantly Reduces Recurrences Through 12 Months GlobeNewswire
08:00AM  Today's Research Reports on Kratos Defense & Security Solutions and pSivida Post Earnings Accesswire
May-05-17 01:45PM  Edited Transcript of PSDV earnings conference call or presentation 4-May-17 8:30pm GMT Thomson Reuters StreetEvents +17.26%
May-04-17 07:00PM  PSivida reports 3Q loss Associated Press
04:01PM  pSivida Corp. Reports Fiscal 2017 Third Quarter Results; Key Milestones on Track GlobeNewswire
09:45AM  Investor Network: pSivida Corp. to Host Earnings Call Accesswire
Apr-19-17 04:01PM  pSivida Corp. to Report Third Quarter Fiscal Year 2017 Financial Results on Thursday, May 4th GlobeNewswire
Apr-11-17 02:23PM  ETFs with exposure to pSivida Corp. : April 11, 2017 Capital Cube
Mar-29-17 08:35PM  ETFs with exposure to pSivida Corp. : March 30, 2017 Capital Cube
08:35PM  ETFs with exposure to pSivida Corp. : March 30, 2017
Mar-20-17 08:30AM  pSivida Corp. :PSDV-US: Earnings Analysis: Q2, 2017 By the Numbers : March 20, 2017 Capital Cube
08:30AM  pSivida Corp. :PSDV-US: Earnings Analysis: Q2, 2017 By the Numbers : March 20, 2017
Mar-15-17 07:00AM  Abstract on pSivida's Treatment of Posterior Segment Uveitis Accepted for Presentation at the 2017 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting GlobeNewswire
Mar-06-17 08:32AM  PSIVIDA CORP. Files SEC form 8-K, Other Events
Feb-15-17 01:04PM  PSIVIDA CORP. Financials
Feb-10-17 07:00AM  pSivida to Present at the 2017 BIO CEO & Investor Conference GlobeNewswire
Feb-09-17 04:18PM  PSIVIDA CORP. Files SEC form 10-Q, Quarterly Report +5.68%
Feb-08-17 04:12PM  PSIVIDA CORP. Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements and Exhibits +6.02%
Feb-07-17 09:19PM  Edited Transcript of PSDV earnings conference call or presentation 7-Feb-17 9:30pm GMT Thomson Reuters StreetEvents
05:30PM  PSivida posts 2Q loss Associated Press
04:04PM  PSIVIDA CORP. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits
04:01PM  pSivida Corp. Reports Fiscal 2017 Second Quarter and First Half Results GlobeNewswire
07:07AM  Q2 2017 pSivida Corp Earnings Release - After Market Close
Jan-25-17 07:00AM  pSivida Corp. Announces Second Quarter Fiscal Year 2017 Financial Results Release Date and Conference Call Information GlobeNewswire
Jan-10-17 04:32PM  PSIVIDA CORP. Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and Exhibits +10.58%
Dec-30-16 08:32AM  PSIVIDA CORP. Files SEC form 8-K, Termination of a Material Definitive Agreement, Change in Directors or Principal Of
Dec-23-16 12:34PM  PSIVIDA CORP. Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and Exhibits +7.07%
Dec-20-16 08:35AM  PSIVIDA CORP. Files SEC form 8-K, Other Events, Financial Statements and Exhibits
Dec-16-16 07:58PM  pSivida Corp. (PSDV): Heres How It Stacks Up Versus Its Peers Insider Monkey +8.12%
07:58PM  pSivida Corp. (PSDV): Heres How It Stacks Up Versus Its Peers at Insider Monkey
04:07PM  PSIVIDA CORP. Files SEC form 8-K, Change in Directors or Principal Officers, Submission of Matters to a Vote of Secur
Dec-13-16 11:45AM  ETFs with exposure to pSivida Corp. : December 13, 2016 -8.24%
Dec-02-16 01:07PM  ETFs with exposure to pSivida Corp. : December 2, 2016
Nov-10-16 12:56PM  ETFs with exposure to pSivida Corp. : November 10, 2016
Nov-09-16 11:57AM  pSivida Corp. :PSDV-US: Earnings Analysis: Q1, 2017 By the Numbers : November 9, 2016
Nov-08-16 01:45PM  PSIVIDA CORP. Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and Exhibits
Nov-07-16 10:39PM  Edited Transcript of PSDV earnings conference call or presentation 7-Nov-16 9:30pm GMT +5.61%
05:04PM  PSivida reports 1Q loss
04:15PM  Seasoned Ophthalmology Executive Deb Jorn Joins pSivida to Focus on Corporate and Commercial Development GlobeNewswire
04:07PM  PSIVIDA CORP. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits
04:01PM  pSivida Corp. Reports Fiscal 2017 First Quarter Results and Provides Update on Corporate Objectives & Milestone Timeline GlobeNewswire
07:07AM  Q1 2017 pSivida Corp Earnings Release - After Market Close
Oct-31-16 07:00AM  pSivida Corp. Announces First Quarter Fiscal Year 2017 Financial Results Release Date and Conference Call Information GlobeNewswire
Oct-28-16 03:15PM  ETFs with exposure to pSivida Corp. : October 28, 2016
Oct-18-16 10:59AM  ETFs with exposure to pSivida Corp. : October 18, 2016
Oct-17-16 09:16AM  pSivida Corp. :PSDV-US: Earnings Analysis: 2016 By the Numbers : October 17, 2016
Oct-04-16 07:00AM  Phase 3 trial of Medidur in Posterior Segment Uveitis Meets Enrollment Target GlobeNewswire
Oct-03-16 11:18AM  ETFs with exposure to pSivida Corp. : October 3, 2016
Sep-28-16 04:03PM  PSIVIDA CORP. Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and Exhibits
Sep-27-16 07:00AM  pSivida Corp. Strengthens Board of Directors With Leading Ophthalmologist GlobeNewswire
Sep-22-16 09:00AM  pSivida to Present at the Ladenburg Thalmann Annual Healthcare Conference GlobeNewswire
Sep-20-16 05:17PM  PSIVIDA CORP. Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and Exhibits
04:01PM  pSivida Reports Inducement Awards to New President and Chief Executive Officer GlobeNewswire
Sep-15-16 11:25AM  Watertown's pSivida appoints new CEO to focus on commercialization at bizjournals.com
07:00AM  pSivida Implements Leadership Change -- Nancy Lurker Named as President and CEO GlobeNewswire
Sep-13-16 02:30PM  PSIVIDA CORP. Files SEC form 10-K, Annual Report
02:03AM  Edited Transcript of PSDV earnings conference call or presentation 12-Sep-16 8:30pm GMT
Sep-12-16 04:17PM  PSivida reports 4Q loss AP
04:02PM  PSIVIDA CORP. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits
04:01PM  pSivida Corp. Provides Company Update and Reports Fourth Quarter and FY 2016 Results GlobeNewswire
07:07AM  Q4 2016 pSivida Corp Earnings Release - After Market Close
Sep-01-16 10:00AM  pSivida Corp. Announces Fourth Quarter and Fiscal Year 2016 Financial Results Release Date and Conference Call Information GlobeNewswire
Aug-29-16 10:00AM  pSivida Announces 13 New Patents Issued or Allowed GlobeNewswire
Aug-15-16 09:00AM  Topline Results from First Phase 3 Trial of pSividas Medidur Presented at ASRS Annual Meeting GlobeNewswire
Aug-09-16 10:00AM  Primary Endpoint Met in pSividas Utilization Study of New Medidur Inserter with Smaller Diameter Needle GlobeNewswire
Aug-03-16 08:00AM  pSivida Names Dario Paggiarino, M.D. as Chief Medical Officer GlobeNewswire
Aug-01-16 07:00AM  pSivida Corp and Hospital for Special Surgery Innovation Center Announce Opening of IND for Sustained-Release Implant for Severe Knee Osteoarthritis GlobeNewswire
Jul-27-16 04:25PM  pSivida Corp.: Strong price momentum but will it sustain?
07:30AM  pSivida's Medidur Maintains Same High Statistical Significance in Primary Endpoint through 12 Months in First Phase 3 Trial (p Less Than 0.00000001) GlobeNewswire
Jul-20-16 12:50PM  ETFs with exposure to pSivida Corp. : July 20, 2016 +5.11%
08:00AM  Data Shows pSividas Tethadur Provides Prolonged, Sustained Release of Avastin® With High Drug Efficacy GlobeNewswire
Jul-18-16 04:03PM  PSIVIDA CORP. Files SEC form 8-K, Costs Associated with Exit or Disposal Activities, Regulation FD Disclosure, Financ
Jul-15-16 08:00AM  pSivida Corp. Announces Plan to Consolidate all Research and Development in Current U.S. Facility GlobeNewswire
Jul-14-16 11:00AM  Investigator-Sponsored Phase 2 Study Results Show pSividas Medidur® Fully Controlled Uveitis for Two Years with No Recurrence of Disease While Visual Acuity Continued to Improve GlobeNewswire +7.36%
Jul-08-16 08:29AM  pSivida Announces Poster and Oral Presentation on Controlled Release of Avastin® from Tethadur Biodegradable Matrix at the 2016 Controlled Release Society Annual Meeting GlobeNewswire
Jul-05-16 08:00AM  pSivida Announces Successful Completion of Two Preclinical Studies of Durasert Sustained-Release Insert Delivering Repurposed Cancer Drug to Treat Wet AMD GlobeNewswire
May-12-16 01:09PM  pSivida Corp. :PSDV-US: Earnings Analysis: Q3, 2016 By the Numbers -5.74%
May-06-16 12:40PM  PSIVIDA CORP. Files SEC form 10-Q, Quarterly Report
May-05-16 06:20PM  PSivida reports 3Q loss AP
04:02PM  PSIVIDA CORP. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits
04:01PM  pSivida Corp. Provides Company Update and Reports Third Quarter FY 2016 Results GlobeNewswire
07:07AM  Q3 2016 pSivida Corp Earnings Release - After Market Close
May-04-16 08:00AM  pSivida CEO to Present at 2016 International Symposium of Ocular Pharmacology and Therapeutics GlobeNewswire
May-02-16 07:30AM  pSividas Medidur for Posterior Uveitis Granted Orphan Drug Designation in Europe GlobeNewswire
Apr-27-16 09:00AM  pSivida Corp. Announces Third Quarter Fiscal Year 2016 Financial Results Release Date and Conference Call Information GlobeNewswire
Mar-24-16 09:10AM  pSivida to Present at the Sidoti Spring 2016 Emerging Growth Convention at noodls
09:00AM  pSivida to Present at the Sidoti Spring 2016 Emerging Growth Convention GlobeNewswire
Mar-15-16 10:00AM  Additional Favorable Six-Month Safety Results for pSivida's Medidur for Posterior Uveitis GlobeNewswire
Feb-11-16 10:51AM  pSivida Corp. Earnings Analysis: Q2, 2016 By the Numbers
Feb-09-16 06:05AM  PSIVIDA CORP. Files SEC form 8-K, Change in Directors or Principal Officers -5.00%
12:01AM  Edited Transcript of PSDV earnings conference call or presentation 8-Feb-16 9:30pm GMT
pSivida Corp. develops sustained-release drug-delivery products for the treatment of chronic eye diseases in the United States and the United Kingdom. It offers ILUVIEN, an injectable, sustained-release micro-insert for use in treating vision impairment associated with diabetic macular edema; and Retisert for the treatment of posterior segment uveitis. The company is also developing Medidur, an injectable, sustained-release micro-insert, which is in Phase III clinical trials for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye. Its pre-clinical development program focuses on developing products using its core platform technologies, Durasert and Tethadur, to deliver drugs and biologics to treat wet and dry age-related macular degeneration, glaucoma, osteoarthritis, and other diseases. The company has strategic collaborations with Alimera Sciences, Inc.; Pfizer, Inc.; Bausch & Lomb Incorporated; and Enigma Therapeutics Limited. pSivida Corp. was founded in 1987 and is headquartered in Watertown, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Lurker NancyPresident and CEOJun 14Buy1.7656,70099,96256,700Jun 14 04:05 PM